These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


878 related items for PubMed ID: 18469090

  • 1. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
    Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L.
    J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
    [Abstract] [Full Text] [Related]

  • 2. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Jul; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 3. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
    Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL, Shemshedini L.
    Oncogene; 2006 Nov 16; 25(54):7212-23. PubMed ID: 16732317
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
    Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM.
    Cancer Res; 2001 Apr 01; 61(7):2892-8. PubMed ID: 11306464
    [Abstract] [Full Text] [Related]

  • 12. Androgen deprivation increases p300 expression in prostate cancer cells.
    Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ.
    Cancer Res; 2007 Apr 01; 67(7):3422-30. PubMed ID: 17409453
    [Abstract] [Full Text] [Related]

  • 13. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM, Frazier MC, Harris WB.
    Anticancer Res; 2007 Apr 01; 27(3B):1483-8. PubMed ID: 17595765
    [Abstract] [Full Text] [Related]

  • 14. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG, Ossowski L, Ferrari AC.
    Cancer Res; 2001 Oct 15; 61(20):7544-51. PubMed ID: 11606392
    [Abstract] [Full Text] [Related]

  • 15. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.
    Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL.
    Cancer Res; 2005 Sep 01; 65(17):7959-67. PubMed ID: 16140968
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL.
    Cancer Res; 2006 Nov 01; 66(21):10594-602. PubMed ID: 17079484
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 44.